Share

October 13, 2020; 95 (15) Article

Diet pattern and prodromal features of Parkinson disease

Samantha Molsberry, Kjetil Bjornevik, Katherine C. Hughes, Brian Healy, Michael Schwarzschild, Alberto Ascherio
First published August 19, 2020, DOI: https://doi.org/10.1212/WNL.0000000000010523
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
343

Share

Article Information

vol. 95 no. 15 e2095-e2108
DOI: 
https://doi.org/10.1212/WNL.0000000000010523
PubMed: 
32817391
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received November 18, 2019
  • Accepted in final form April 28, 2020
  • First Published August 19, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Samantha Molsberry, PhD,
    2. Kjetil Bjornevik, MD, PhD,
    3. Katherine C. Hughes, ScD,
    4. Brian Healy, PhD,
    5. Michael Schwarzschild, MD, PhD and
    6. Alberto Ascherio, MD, DrPH
  1. Samantha Molsberry, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kjetil Bjornevik, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Frontiers in Neurology, Editorial board, 2017 - present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The ALS Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Katherine C. Hughes, ScD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. UnitedHealth Group, Epidemiologist, 1 year

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Department of Defense, grant number W81XWH-14-0131, graduate student/postdoctoral fellow, 2014-2018 Stock/Stock Options, Medical Equipment & Materials: UnitedHealth Group, 1 year

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Brian Healy, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Statistical methods in medical research, editorial board, 2007-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Merck Serono, S.A. (2) Novartis (3) Genzyme (4) Verily Life Sciences (5) Analysis Group

    Research Support, Government Entities:

    1. (1) NIH, 1R21NR018738, Biostatistician, 2020-present (2) NIH, P50MH115846-01A1, Biostatistician, 2019-present (3) NIH, 5UL1TR002541, Biostatistician, 2018-present (4) NIH, R01HL133149-03, Biostatistician, 2017-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Michael Schwarzschild, MD, PhD and
    6. Scientific Advisory Boards:

    1. (1) Michael J. Fox Foundation for Parkinson's Research SAB (New York, NY) [2017-2019] (2) Cure Parkinson's Trust foundation Linked Clinical Trials program SAB (London, UK) [∼2012- ] (3) Corticobasal Degeneration Solutions Foundation SAB (Stockholm, Sweden) (4) NINDS/Udall Center of the Brigham & Womens Hospital -- Internal Advisory Committee (Boston, MA) (5) Eli Lilly & Company (clinical trial DSMB service); 2018- (6) Prevail Therapeutics (clinical advisory board); 2018-2019 (7) Parkinson's Foundation (Genetics initiative advisory board); 2018- (8) X-linked Dystonia Parkinsonism Clinical Center; 2018- (9) Denali Therapeutics (clinical advisory board); 2019 (10) Chase Therapeutics (clinical development advisory board); 2019-2020

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. •Denali Therapeutics, seminar speaker (2019) All others are non-profit entities: •Krembil Conference (Toronto) lecture (2019) •Xuanwu Hospital (Beijing) symposium lecture (2018) •Thomas Jefferson University, grand rounds lecture (2018) •International Association of Parkinson's disease and Related Disorder, Melvin Yahr lecture (2018) •World Parkinson Congress, travel/honorarium (2006,2010,2013,2016,2019) •Parkinson Study Group symposium/meeting •for Cure Parkinson's Trust program SAB mtg. (Windsor, UK; Grand Rapids, MI) •for Cure Parkinson's Trust program SAB mtg. (Grand Rapids, MI); (travel)

    Editorial Boards:

    1. Journal of Adenosine and Caffeine Research, Editorial advisory board (2018-) Parkinsonism and Related Disorders, Editorial advisory board (2018-)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Massachusetts General Hospital (sole employer; non-profit)

    Consultancies:

    1. (1) Harvard University (Parkinson's disease case reviews and epidemiology research); ∼2002-present (2) New Beta-Innovations, Inc (Hong Kong); 2016 (3) Eli Lilly & Company (clinical trial DSMB service); 2018- (4) Prevail Therapeutics, Inc (New York City); 2018-2019 (5) nQ Medical (Cambridge, MA); 2019 (6) Denali Therapeutics (Nice, France); 2019 (7) Chase Therapeutics (Washington, DC); 2019

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. •NIH R01 NS110879 (PI) 08/01/19 – 05/31/24 •NIH U01 NS107009 (a PI) 07/01/18 to 04/30/23 •NIH R13 NS111953 (PI) 04/01/19 – 03/31/22 •NIH U01 NS090259 (PI) 9/1/2015 to 6/30/2020 •NIH U13 NS103523 (PI) 07/01/17 - 06/30/18 •NIH R13 NS098746 (PI) 07/01/16 - 06/30/17 •DoD W81XWH-14-1-0131 (Collaborator [A. Ascherio, PI]) 05/15/14 - 05/14/15 •NIH R21 NS090246 (Co-Investigator [Xiqun Chen, PI]) 04/01/15 - 03/31/17 •NIH R01 (Collaborator [A. Ascherio, PI]) •NIH R13 NS090879 (PI) 09/22/14 - 08/31/15 •R21 NS084710 (dual PI: Schwarzschild) 7/1/13-6/30/15 NIH/NINDS “Role of urate in protecting mitochondrial function in the brain” •K24 NS060991 (PI: Schwarzschild) 7/1/08-6/30/13 NIH/NINDS "Pursuing Puringergic Pathways to Clinical Trials for Parkinson's Disease" •DoD NETRP W81XWH-11-1-0150 (PI: Schwarzschild) 1/17/11 – 1/16/16 Dept of Defense / USAMRAA (Parkinson’s research program) "Protection by Purines in Toxin Models of Parkinson's Disease" •NIH/NINDS RO1 NS061858 (PI: A. Ascherio) 4/15/2009 - 3/31/2014 “Urate predictor Parkinson's Disease Risk and Progression” Role: Collaborator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. grant support via my institution (MGH) on projects for which I am the Principal Investigator: (1) Michael J. Fox Foundation (2) Parkinson's Foundation (3) Farmer Family Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Adenosine A2A receptor knockout mice, MGH (which receives payments from The Jackson Laboratory via licensing agreements); ∼2001-present (2) floxed urate oxidase mice, MGH; 2020-

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Alberto Ascherio, MD, DrPH
    7. Scientific Advisory Boards:

    1. University of Rochester - Scientific Advisory Board of NIH-funded study "At-Home PD"

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. NorthShore University HealthSystem, Evanston IL, 2019. Honorarium for talk on neurodegenerative diseases. University of Oslo, Norway. Honorarium as PhD defense opponent.

    Editorial Boards:

    1. 1) Journal of Parkinson Disease, Editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01 NS073633; 2011-2017; Role: PI DoD W81XWH-14-1-0131; 2014-2019; Role: PI NIH R01 NS045893; 2013-2018; Role: PI NIH 1U01NS-90259; 2015-2020; Role: PI of subcontract NIH R01 NS089619-01A1; 2015-2020; Role: PI NIH R01 NS097723; 2016-2021; Role: Co-Investigator NIH R01 NS103891; 2018-2023; Role: PI CDMRP MS170116; 2018-2021; Role: PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. ALS Association; 2019-2020; Role: PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Population Health Sciences Program (S.M.), Harvard University, Cambridge; Departments of Nutrition (K.B., K.C.H., A.A.) and Epidemiology (A.A.), Harvard T.H. Chan School of Public Health; Partners Multiple Sclerosis Center (B.H.), Brigham and Women's Hospital; Department of Neurology (M.S.), Massachusetts General Hospital; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  1. Correspondence
    Dr. Molsberry sam306{at}mail.harvard.edu
View Full Text

Article usage

Article usage: August 2020 to February 2023

AbstractFullPdfSource
Aug 20203176046Highwire
Sep 20201548048Highwire
Oct 202019549146Highwire
Nov 20204161918Highwire
Dec 20203951413Highwire
Jan 20213152118Highwire
Feb 20212692021Highwire
Mar 20213061617Highwire
Apr 20212941117Highwire
May 2021234147Highwire
Jun 202119078Highwire
Jul 202115745Highwire
Aug 202118863Highwire
Sep 202117675Highwire
Oct 202125046Highwire
Nov 2021174115Highwire
Dec 2021123137Highwire
Jan 202212175Highwire
Feb 20228946Highwire
Mar 202213830Highwire
Apr 202212744Highwire
May 202215366Highwire
Jun 202210553Highwire
Jul 202211632Highwire
Aug 202213072Highwire
Sep 202214823Highwire
Oct 2022152139Highwire
Nov 202215063Highwire
Dec 20229931Highwire
Jan 202310543Highwire
Feb 202311766Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me

Recommended articles